QNCX FY2029 EPS Increased by Brookline Capital Management

Key Points

• Brookline Capital Management has increased its FY2029 earnings per share estimate for Quince Therapeutics from $0.48 to $0.54, while the consensus estimate for the company's current full-year earnings is ($1.21) per share.
• Quince Therapeutics reported a quarterly EPS of (\$0.34), missing the consensus estimate of (\$0.28) by (\$0.06) during its last earnings announcement on August 11th.
• Institutional investors have been active, with several hedge funds, including Geode Capital Management and Northern Trust, boosting their stakes in Quince Therapeutics, indicating increased confidence in the company's future performance.

Quince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) - Analysts at Brookline Capital Management raised their FY2029 earnings per share estimates for Quince Therapeutics in a report released on Tuesday, August 12th. Brookline Capital Management analyst K. Raja now expects that the company will post earnings per share of $0.54 for the year, up from their previous estimate of $0.48. The consensus estimate for Quince Therapeutics' current full-year earnings is ($1.21) per share.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06).

Other research analysts also recently issued research reports about the company. D. Boral Capital reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Quince Therapeutics in a research note on Thursday, July 17th. JMP Securities decreased their target price on Quince Therapeutics from $9.00 to $8.00 and set a "market outperform" rating on the stock in a research note on Tuesday. Citigroup assumed coverage on Quince Therapeutics in a research note on Tuesday, August 5th. They set an "outperform" rating on the stock. Citizens Jmp started coverage on Quince Therapeutics in a research note on Tuesday, August 5th. They set a "strong-buy" rating and a $9.00 target price on the stock. Finally, Wall Street Zen cut Quince Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Quince Therapeutics has an average rating of "Buy" and an average target price of $8.14.

Quince Therapeutics Stock Performance

Shares of NASDAQ QNCX traded down $0.04 during trading on Thursday, hitting $1.69. The company had a trading volume of 52,813 shares, compared to its average volume of 238,834. The stock has a 50 day simple moving average of $1.59 and a 200 day simple moving average of $1.37. The company has a debt-to-equity ratio of 1.45, a quick ratio of 4.05 and a current ratio of 5.00. Quince Therapeutics has a 12 month low of $0.51 and a 12 month high of $2.45. The firm has a market capitalization of $90.51 million, a P/E ratio of -1.55 and a beta of 1.02.

Hedge Funds Weigh In On Quince Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of QNCX. Geode Capital Management LLC boosted its holdings in shares of Quince Therapeutics by 10.9% in the 4th quarter. Geode Capital Management LLC now owns 375,932 shares of the company's stock worth $703,000 after purchasing an additional 36,807 shares during the period. Northern Trust Corp boosted its holdings in shares of Quince Therapeutics by 48.5% in the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company's stock worth $94,000 after purchasing an additional 16,501 shares during the period. Shay Capital LLC boosted its holdings in shares of Quince Therapeutics by 60.8% in the 4th quarter. Shay Capital LLC now owns 276,799 shares of the company's stock worth $518,000 after purchasing an additional 104,616 shares during the period. Two Sigma Investments LP purchased a new position in shares of Quince Therapeutics in the 4th quarter worth approximately $57,000. Finally, Intellectus Partners LLC purchased a new position in shares of Quince Therapeutics in the 1st quarter worth approximately $71,000. Hedge funds and other institutional investors own 30.75% of the company's stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.